EGCG has been shown to be able to induce dose-dependent (5–80 μM) apoptotic cell death in estrogen receptor- (ER-) independent breast cancer cells via an increased Bax to Bcl-2 protein ratio and p53 expression [106]. Here, TP53 is linked to breast carcinoma.